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Kolding, Copenhagen, Hvidovre, and Odense, DenmarkBackground: Recurrent wheeze (RW) is frequent in childhood.
Studies have suggested that BCG vaccination can have
nonspecific effects, reducing general nontuberculosis morbidity,
including respiratory tract infections and atopic diseases. The
mechanisms behind these nonspecific effects of BCG are not
fully understood, but a shift from a TH2 to a TH1 response has
been suggested as a possible explanation.
Objective: We hypothesized that BCG at birth would reduce the
cumulative incidence of RW during the first year of life.
Methods: The Danish Calmette Study is a multicenter
randomized trial conducted from 2012-2015 at 3 Danish
hospitals. The 4262 newborns of 4184 included mothers were
randomized 1:1 to BCG (SSI strain 1331) or to a no-intervention
control group within 7 days of birth; siblings were randomized
together as one randomization unit. Exclusion criteria were
gestational age of less than 32 weeks, birth weight of less than
1000 g, known immunodeficiency, or no Danish-speaking
parent. Information was collected through telephone interviews
and clinical examinations at 3 and 13 months of age; data
collectors were blind to randomization group. RW was defined
in several ways, with the main definition being physician-
diagnosed and medically treated RW up to 13 months of age.
Results: By 13 months, 211 (10.0%) of 2100 children in the BCG
group and 195 (9.4%) of 2071 children in the control group had
received a diagnosis of RW from a medical doctor and received
antiasthma treatment (relative risk, 1.07; 95% CI, 0.89-1.28).From athe Department of Pediatrics, Kolding Hospital, and the Institute of Regional
Health Research, University of Southern Denmark, Kolding; bthe Department of Pae-
diatrics and Adolescent Medicine, Juliane Marie Centret, Rigshospitalet, Copenhagen
University Hospital, Copenhagen; cthe Research Unit for Women’s and Childrens’
Health, Department of Paediatrics and Adolescent Medicine, Juliane Marie Centret,
Rigshospitalet, Copenhagen University Hospital, Copenhagen; dthe Department of Pe-
diatrics, Copenhagen University Hospital, Hvidovre; ethe Research Center for Vita-
mins and Vaccines (CVIVA), Bandim Health Project, Statens Serum Institut, and
the Section of Biostatistics, University of Copenhagen; fthe Bandim Health Project,
Statens Serum Institut, Copenhagen; gthe Department of Obstetrics and Gynecology,
Odense University Hospital; hthe Research Center for Vitamins and Vaccines
(CVIVA), Statens Serum Institut, Copenhagen, and OPEN, Institute of Clinical
Research, University of Southern Denmark/Odense University Hospital, Odense.
Supported by the Danish National Research Foundation (DNRF 108) and the 3 involved
hospitals (Danish National Hospital in Copenhagen, Hvidovre Hospital, and Kolding
Hospital). The BCG vaccine was produced by Statens Serum Institute, Copenhagen,
Denmark, and bought by the Danish Calmette Study.
Disclosure of potential conflict of interest: L. G. Stensballe and J. Kjærgaard have
received a grant from the Danish National Research Foundation (DNRF 108). A. K. G.
1616Supplementary analyses were made, including an analysis of
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Conclusion: Neonatal BCG had no effect on the development of
RW before 13 months of age. (J Allergy Clin Immunol
2017;140:1616-21.)
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Especially during the winter season, recurrent wheeze (RW) is
frequent in young children in high-income countries, where every
third child less than 6 years of age has been reported to have
asthma-like symptoms during the preceding winter.1 A task force
under the European Respiratory Society recommends the division
of RW into ‘‘episodic viral wheeze,’’ which is exclusively triggered
by viral airway infections, and ‘‘multiple trigger wheeze,’’ when
the wheezing is also present between episodes of airway tract
infections.2 Thus RW is closely linked to airway infections but
not necessarily to atopy and allergy2,3; in fact, differential effects
of risk factors on infant wheeze and atopic dermatitis emphasize
a different etiology.4 However, the treatment used for RW is
essentially the same as the symptomatic treatment used for
asthmatic children because many of the symptoms are similar.2
BCG vaccine is recommended to prevent tuberculosis,5 but as
shown in 2 systematic reviews,6,7 BCG has also been suggested as
a protective measure against atopy. According to the hygieneJensen and C. S. Benn have received grants from the Danish National Research
Foundation. The rest of the authors declare that they have no relevant conflicts of
interest.
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some of the increase in the incidence of atopic diseases observed
in recent decades. BCG has been shown to cause a strong
immunologic stimulation, resulting in an IFN-g response,9 which
could counterbalance the greater TH2 response found in atopic
subjects.10 However, the picture is much more complicated than
just a TH1 response instead of a TH2 response, and the exact
mechanism of the BCG effect on a cellular level has been the
subject of immunologic research in recent years. An English
questionnaire–based study published in 2007 found neonatal
BCG vaccination associated with a significant reduction in
asthma symptoms in children aged 6 to 11 years.11 However, an
updated systematic review from 2014 found any protective effect
of BCG against asthma likely to be transient.7
Randomized clinical trials (RCTs)12,13 and observational
studies14-16 have supported that BCG can have beneficial nonspe-
cific effects (NSEs) reducing all-causemorbidity andmortality. In
West Africa early BCG vaccination of low-birth-weight infants
decreased neonatal mortality, mainly by reducing the incidence
of neonatal sepsis, respiratory tract infections, and fever.12
Since the beginning of the 1980s, BCG is no longer a part of the
Danish Childhood Vaccination Program, and BCG vaccination is
now only recommended for specific risk groups.
The Danish Calmette Study aimed to study NSEs of neonatal
BCG vaccination in a high-income country. The RCT was
powered to study hospital admissions as the primary outcome
and atopic dermatitis as a secondary outcome.17
Based on the observed effect of BCG on respiratory tract
infections and the link between respiratory tract infections and
RW, we hypothesized that neonatal BCG would reduce the
cumulative incidence of RW in the first year of life. The aim of
the present study was to determine the effect of neonatal BCG on
the secondary outcome of cumulative incidence of physician-
diagnosed and medically treated RW up to 13 months of age.METHODS
The Danish Calmette Study was an RCT conducted at 3 Danish hospitals.
Newborns were enrolled from October 2012 to November 2013. Exclusion
criteria were gestational age of less than 32 weeks, birth weight of less than
1000 g, known immunodeficiency, or no Danish-speaking parent. Within
7 days of birth, the newborns were allocated 1:1 to BCG vaccination (SSI
strain 1331) or no intervention; in case of multiple births, siblings were
randomized together as one randomization unit. The randomization was
stratified by maturity. Before randomization, informed consent was obtained,
and a structured telephone interview was conducted to collect data on
demographics and atopic predisposition. Follow-up consisted of telephone
interviews and clinical examinations at 3 and 13 months of age. The methods
have been described in detail elsewhere.17Outcome assessment
The main outcome of the present study was the cumulative incidence of
physician-diagnosed and medically treated RW until 13 months of age,according to telephone interviews at 3 and 13 months of age. In telephone
interviews parents were asked whether their child had ever had RW since birth
(3-month interview) or since the last interview (13-month interview). If that
was the case, they were asked about use of antiasthma treatment, duration of
the treatment, and whether the diagnosis had been confirmed by a medical
doctor. At both 3 and 13 months of age, the parents were asked whether their
child also had wheezing in periods without respiratory tract infections. At
13 months of age, they were asked whether their child had been coughing at
night in periods without respiratory tract infections and whether the child had
exercise-induced dyspnea.
RW is defined by recurrent episodes of wheeze, and thus at least 2 episodes
of wheeze must have been observed to use the diagnosis of RW. Generally, in
Denmark the clinical diagnosis of RW is used for children with 3 or more
episodes of wheezing. The Danish term for RW is ‘‘asthmatic bronchitis,’’ a
term primarily used by persons who have been in contact with the health care
system.
At 3 and 13 months, the children were invited for a clinical
examination at the study site, where study staff evaluated the child’s breathing
and made an auscultation. Telephone interviews were conducted by medical
doctors, nurses, midwives, and medical students. Clinical examinations
were conducted by medical doctors, specially trained nurses, and medical
students.Blinding
During telephone interviews and at clinical examinations, parents were
instructed not to reveal the BCG vaccination status of the child to the study staff
and to cover the vaccination site on the left shoulder with a plaster before the
clinical examinations, irrespective of the child’s randomization group.Definition of atopic predisposition
A child was considered to have atopic predisposition if at least 1
first-degree relative (biological parent or full sibling) currently had or
previously had 1 or more of the following atopic diseases with a diagnosis
from a medical doctor: food allergy, atopic dermatitis, hay fever, or asthma.
RW exclusively triggered by viral airway infections was not considered an
atopic disease.Definition of RW outcome
We defined RWas physician-diagnosed andmedically treated RWbased on
confirmative answers given by the parents to both of the following 2 questions
in the telephone interview at 13 months of age: ‘‘Has a doctor said that your
child has (had) RW?’’ and ‘‘Has the RW been treated with anti-asthmatic
treatment?’’ All types of antiasthma treatment were included: b2-agonists,
long-acting b-agonists, inhaled glucocorticoids, systemic glucocorticoids,
and leukotriene receptor antagonists.
Objective signs of RW from the clinical examination were used as a
secondary outcome.
The main definition of RW proposed in the analysis plan included all
cases of parent-suspected RW, all RW diagnoses given by a medical doctor,
and all signs of RW found at the clinical examinations of the Danish
Calmette Study, including any rhonchus or prolonged expiration heard at
auscultation.
The more specific definition of RW mentioned in the analysis plan was
‘‘clinically diagnosed RW,’’ which was RW diagnosed by a medical doctor or
by the Danish Calmette Study staff. A prior publication has documented a
higher specificity of diagnosis-based than symptoms-based questions
regarding asthma, allergic rhinitis, and conjunctivitis.18 Although the present
study looked for RW (and not asthma), the samemight apply for RW. Post hoc,
we decided to emphasize thismore specific definition and further enhanced the
specificity of the diagnosis by requiring both an RW diagnosis given by a
medical doctor and treatment with antiasthma medication.
For comparison, results with respect to the broadly predefined diagnosis
from the analysis plan are shown in Table E1 in this article’s OnlineRepository
at www.jacionline.org.
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If a child did not participate in the 3-month follow-up, the telephone
interview at 13months of age covered the time since birth. In case of no known
atopic predisposition but uncertainty about 1 or 2 subquestions (mostly
whether the father had had AD), the child was coded as ‘‘no atopic
predisposition.’’ A sensitivity analysis, in which children with such
uncertainty were excluded, did not change the main results (data not shown).
Statistical analyses
The statistical analysis plan was deposited with the Data and Safety
Monitoring Board before the study was unblinded. The primary analysis was
intention to treat. The cumulative incidences of RW in the 2 randomization
groups were compared by using log-binomial regression, resulting in risk
ratios (RRs)with 95%CIs. This statisticalmodel assumes full follow-up for all
participants, and therefore the main analyses of the present study were based
on the 4,171 children (97.9% of the randomized children), who answered the
questions about RW in the telephone interview at 13 months of age.
The randomization was stratified by maturity (>_37 weeks vs <37 weeks of
gestation), and thus all results were adjusted for maturity.
There were 73 pairs of twins among the RW cohort of 4,171 children;
because all siblings were randomized together as one randomization unit, both
twins of the same mother received the same treatment. Supplementary
cluster-adjusted analyses linking outcomes in twins weremade, which derived
almost identical SEs as the main analyses. Thus the results reported are
without cluster adjustment.
Completion rate and distribution of background factors among the children
lost to follow-up in the 2 allocation groups were compared by using the x2 test.Subgroup analyses
Because previous studies of NSEs of BCG have emphasized children with
atopic predisposition,19 and shown differential effects by sex12,20 andmaternal
immunity,21 it was prespecified to conduct the analyses stratified by these
subgroups. Specifically, because BCG was recommended for schoolchildren
in Denmark until the late 1970s/early 1980s, some mothers had been BCG
vaccinated but most had not, permitting an analysis of possible effect modifi-
cation by maternal BCG vaccination status. Furthermore, we prespecified
analyses for possible effect modification by factors previously found to be
associated with the development of atopic diseases (ethnicity, number of
siblings, pets at home, smoking, breast-feeding, and institutional child care).
A study reported that timing of BCG vaccination might be important,
finding a stronger protective effect on atopy among children who were BCG
vaccinated in the first week of life.22 We prespecified an analysis stratified by
age at randomization (days 0-1 vs days 2-7).Sensitivity analyses
As a supplement to the main analysis of physician-diagnosed and medically
treated RW, we conducted sensitivity analyses with different definitions of RW:
parent-suspected RW, physician-diagnosed RW, andmedically treated RW.We
also tested whether the conclusions were similar at the 3 inclusion sites.Risk factor analysis
For the risk factor analysis, the cumulative incidences of RW in the
predefined subgroups of potential effect modifiers were compared by using
log-binomial regression, resulting in RRs with 95% CIs.
P values of less than .05 were considered statistically significant, and all
tests were 2-sided. STATA 14 software (StataCorp, College Station, Tex)
was used for the analyses.Sample size
The Danish Calmette Study was powered to detect an effect of BCG on
all-cause hospitalizations and atopic dermatitis.17 In the RW cohort of 4171
children, we had an incidence of RWof 9.7%. Thus wewould be able to detect
a 25% protection against RW with a power of 80% and an a value of 5%.Ethics
The Danish Calmette Study was approved by the Danish Data
Protection Board (2009-41-4141), the Committees on Biomedical Research
Ethics (H-3-2010-087), and the Danish Medicines Agency (2612-4356,
EudraCT 2010-021979-85, Protocol 2009-323). The study was registered at
www.ClinicalTrials.gov (NCT01694108) and supervised byGoodClinical Prac-
tice Units and an independent Data and Safety Monitoring Board. All parents
provided verbal and written consent to allow their child to participate in the trial.RESULTS
From October 2012 to November 2013, 16,521 pregnant
women were identified at the 3 recruitment sites, and 4,262
newborn infants born of 4,184 women were randomized.17
Non-Danish ethnicity (18.0% vs 21.9%) and paternal smoking
during pregnancy (18.5% vs 21.9%) were more frequent in the
control group; otherwise, background factors were evenly
distributed.23 Atopic predisposition was reported for 63% of the
enrolled families (2,639/4,184).
Of the 4,262 included children (2,129 BCG/2,133 control group),
4,192 (98.4%) were interviewed by telephone at 13 months of age,
and of these, 4,171 (97.9%of the randomized children) answered the
questions regarding RW, generating the cohort for the present study.
Fewer children were lost to follow-up in the BCG group (n 5 29;
completion rate, 98.6%) compared with the control group (n5 62;
completion rate, 97.1%; P < .001). Among the children lost to
follow-up, there were no differences in background characteristics
between the 2 allocation groups (data not shown). The median age
at the last telephone interview was 375 days (10% to 90%
percentiles: 370-390 days) in the BCG group and 375 days
(10% to 90% percentiles: 371-392 days) in the control group.BCG and RW
At 13 months of age, 211 (10.0%) of 2100 children in the BCG
group and 195 (9.4%) of 2071 children in the control group had
RW, which was diagnosed by a medical doctor and treated with
antiasthma medication. Thus there was no difference between the
2 randomization groups in the risk of physician-diagnosed and
medically treated RW in the first year of life, with the RR being
1.07 (95% CI, 0.89-1.28; Table I). The estimate was unchanged if
we adjusted for the 2 factors that were unevenly distributed
among the randomization groups (data not shown).
At 13 months of age, less than 20% of the children with
physician-diagnosed and medically treated RW received
treatment for at least 2 months (Table I). For this and the other
measures of severity of RW, there was no significant difference
in the effect of BCG between the 2 randomization groups
(Table I); however, the risk of wheezing without having a cold
tended to be higher among BCG-vaccinated children (RR, 1.38;
95% CI, 1.00-1.92).Subgroup analyses
With the exception of number of siblings, we found no effect
modification with BCG by the prespecified potential effect
modifiers (Table I). BCG tended to increase the risk of RWamong
children without older siblings (Table I) but had no such effect in
children with older siblings.
Therewas little variation in the age of vaccination, and the effect
of BCGdid not differ significantly between children vaccinated on
days 0 to 1 versus days 2 to 7 (Fig 1). Three thousand one hundred
TABLE I. Physician-diagnosed and medically treated RW in the first year of life in relation to neonatal BCG vaccination and
potential effect modifiers*
Parameter analyzed
BCG group,
no. with RW/total no. (%)
Control group,
no. with RW/total no. (%)
RR (95% CI) for
BCG effect on RW
Test of no
interaction
(P value)
Primary outcome: intention-to-treat analysis:
Physician-diagnosed and medically treated RW
211/2100 (10.0%) 195/2071 (9.4%) 1.07 (0.89-1.28)
Different measures of severity of RW
Antiasthma treatment for >_2 mo 57/2100 (2.7%) 49/2071 (2.4%) 1.15 (0.79-1.67)
Symptoms between episodes with respiratory tract infections
Wheezing without having a cold 83/2100 (4.0%) 59/2071 (2.8%) 1.38 (1.00-1.92)
Coughing at night without having a cold 89/2100 (4.2%) 98/2071 (4.7%) 0.90 (0.68-1.19)
Exercise-induced dyspnea without having a cold 59/2100 (2.8%) 49/2071 (2.4%) 1.19 (0.82-1.72)
Current use of prophylactic treatment
Inhaled steroid 41/2044 (2.0%) 35/1946 (1.8%) 1.11 (0.71-1.74)
Montelukast 3/2044 (0.1%) 5/1946 (0.3%) 0.57 (0.14-2.39)
RW in relation to potential effect modifiers
GA at birth
Premature (GA 3210 to 3616; n 5 133) 9/68 (13.2%) 6/65 (9.2%) 1.43 (0.54-3.80) .55
Mature (GA >_3710; n 5 4038) 202/2032 (9.9%) 189/2006 (9.4%) 1.06 (0.87-1.27)
Sex
Boys (n 5 2199) 132/1093 (12.1%) 126/1106 (11.4%) 1.06 (0.84-1.33) .87
Girls (n 5 1972) 79/1007 (7.8%) 69/965 (7.2%) 1.10 (0.80-1.50)
Atopic predisposition (missing: 73)
With atopic predisposition (n 5 2630) 142/1334 (10.6%) 124/1296 (9.6%) 1.11 (0.88-1.40) .62
Without atopic predisposition (n 5 1468) 68/727 (9.4%) 69/741 (9.3%) 1.01 (0.73-1.38)
Maternal BCG status (missing: 51)
Mother BCG vaccinated (n 5 724) 28/366 (7.7%) 23/358 (6.4%) 1.19 (0.70-2.03) .26
Mother not BCG vaccinated (n 5 3396) 178/1712 (10.4%) 170/1684 (10.1%) 1.03 (0.84-1.26)
Ethnicity (missing: 25)
Non-Danish ethnicity (n 5 824) 39/369 (10.6%) 31/455 (6.8%) 1.56 (0.99-2.45) .06
Danish ethnicity (n 5 3322) 172/1719 (10.0%) 164/1603 (10.2%) 0.98 (0.80-1.20)
Siblings (missing: 2)
At least 1 older sibling (n 5 1724) 109/893 (12.2%) 116/831 (14.0%) 0.87 (0.68-1.11) .03
No older siblings (n 5 2445) 102/1207 (8.5%) 79/1238 (6.4%) 1.33 (1.00-1.76)
Pets at home
Yes (n 5 1225) 77/638 (12.1%) 74/587 (12.6%) 0.96 (0.71-1.29) .40
No (n 5 2946) 134/1462 (9.2%) 121/1484 (8.2%) 1.12 (0.89-1.42)
Smoking status by 13 mo of age (missing: 36)
Ever smoked since birth of child (n 5 1157) 68/563 (12.1%) 63/594 (10.6%) 1.14 (0.83-1.57) .62
Never smoked since birth of child (n 5 2978) 141/1519 (9.3%) 131/1459 (9.0%) 1.03 (0.82-1.30)
Breast-feeding (missing: 7)
Not fully breast-fed until 3 mo (n 5 1801) 102/892 (11.4%) 91/909 (10.0%) 1.14 (0.88-1.49) .50
Fully breast-fed until 3 mo of age (n 5 2363) 109/1205 (9.0%) 104/1158 (9.0%) 1.01 (0.78-1.30)
Started institutional child care before 13 mo of follow-up (missing: 1)
Yes (n 5 3584) 198/1820 (10.9%) 179/1764 (10.1%) 1.07 (0.89-1.30) .62
No (n 5 586) 13/280 (4.6%) 16/306 (5.2%) 0.89 (0.43-1.81)
GA, Gestational age.
*Log-binomial regression analysis of the 4171 children who answered questions regarding RW in the telephone interview at 13 months of age (97.9% of randomized children).
Based on information from the telephone interview at 13 months of age, in which 2100 children from the BCG group and 2071 children from the control group participated.
Based on information from the clinical examination at 13 months of age, in which 2044 children from the BCG group and 1946 children from the control group participated.
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0 or 1 and 1011 (24.2%) of 4171 on days 2 to 7.Sensitivity analyses
The sensitivity analyses with different definitions of RW
yielded similar results (see Table E2 in this article’s Online
Repository at www.jacionline.org). Only very few children had
RWbefore 3months of age. In the telephone interview at 3months
of age, the cumulative incidence of physician-diagnosed and
medically diagnosed RWwas 7 (0.3%) of 2117 in the BCG group
and 7 (0.3%) of 2108 in the control group (RR, 0.99; 95% CI,
0.35-2.83).The results of the broad definition of RW mentioned in the
analysis plan and reported in Table E1 are comparable with the
main results in Table I: with the broad definition, there was no
effect of BCG on the main outcome, and with the exception
of number of siblings, we found no effect modification (see
Table E1).
The cumulative incidence of RW differed between the 3
different inclusion sites, with a P value of less than .001 in the
test of no interaction (cumulative incidence of RW at site 1:
9.2% [131/1417], cumulative incidence of RW at site 2: 13.3%
[161/1211], and cumulative incidence of RW at site 3: 7.4%
[114/1543]). However, the effect of BCG was the same across
the 3 sites, with a P value of .83 in the test of no interaction
FIG 1. Physician-diagnosed and medically treated RW in first year of life in
relation to age in days at randomization. Day 0 is the date of birth.
Log-binomial regression analysis on the 4171 children for whom the
questions regarding RW were answered in the telephone interview at
13 months of age was performed. *Test of same effect of BCG (P 5 .08).
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0.77-1.47], RR in BCG-vaccinated children at site 2: 0.97 [95%
CI, 0.73-1.30], and RR in BCG-vaccinated children at site 3:
1.11 [95% CI, 0.78-1.59]).
Risk factor analysis
As previously shown, male sex, siblings, pets, parental
smoking, and daycare attendance were associated with a higher
risk of RW, and breast-feeding showed a tendency toward a lower
risk of RW (see Table E3 in this article’s Online Repository at
www.jacionline.org). Children of mothers who were BCG
vaccinated had a 31% (9% to 48%) lower risk of RW than children
of BCG-unvaccinated mothers, but RW was not associated with
prematurity, atopic predisposition, or ethnicity (see Table E3).
In a multivariable analysis male sex, siblings, pets, parental
smoking, breast-feeding, and daycare attendance were
significantly associated with RW (see Table E3).
DISCUSSION
Randomization to neonatal BCG vaccination had no influence
on the cumulative incidence of RW by age 13 months.
Comparison with other studies
The results of our RCTare comparable with those from a small
Dutch RCT, which in 1999-2002 enrolled 121 children with
atopic predisposition and randomized them to BCG or no BCG at
6 weeks of age.19 They found no effect of BCG against asthma-
related symptoms until 18 months of age. However, because of
its size, the Dutch trial would only have captured very large
effects.19 In contrast, our RCT found a protective effect of BCG
on the risk of atopic dermatitis in children with atopic predisposi-
tion (authors’ unpublished results), and the Dutch RCT found a
protective effect on the use of medication against eczema.19
Thus, based on these 2 RCTs, the only ones conducted in
high-income countries, BCG might protect children with atopic
predisposition against atopic dermatitis but not against RW. The
differential effect of BCG on atopic dermatitis and RW empha-
sizes that RW is not an atopic disease, and as previously shown,
the risk factors for atopic dermatitis and RW are very different.4Whether BCG has an effect on atopic asthma in older children
still remains to be tested. Our choice of RWas an outcome instead
of asthma was caused by the follow-up time of 13 months in our
RCT.
In a systematic review from 2011 on the association between
BCG and allergy (mostly in schoolchildren), the protective effect
of BCG on asthma was insignificant when tested in subgroups,
and there was evidence suggestive of publication bias and
heterogeneity.6
In an updated systematic review and meta-analysis from 2014,
including results from theManchester Community Asthma Study
(MANCAS) on children 6 to 11 years of age, Linehan et al7
evaluated that the protective effect of neonatal BCG against the
risk of wheeze at age 6 to 11 years initially found in MANCAS
could not be found in the MANCAS cohort when the children
were 13 to 17 years old. Thus the authors concluded that any
protective effect of neonatal BCG vaccination on childhood
asthma was likely to be transient.
The Danish Calmette Study found no overall association
between BCG and the registry-based primary outcome of
all-cause hospitalizations.23 Furthermore, there was no overall
effect of BCG on the secondary outcomes of hospitalization for
infectious diseases (personal communication), parent-reported
infectious diseases, or general practitioner visits.24 However,
the risks of hospitalization for infection and for parent-reported
infectious disease were observed to be significantly decreased
among BCG-vaccinated children whose mothers were also
BCG vaccinated (personal communication).24 Although RW is
closely linked to respiratory tract infections, there was no
indication that the effect of BCG vaccination on RW was
particularly beneficial in children of BCG-vaccinated mothers,
although the risk of RW was generally decreased in children of
BCG-vaccinated mothers.
Because the power calculation wasmade for themain outcome,
subgroup analyses might not have sufficient power. According to
Fig 1, we cannot exclude that children vaccinated on days 2 to 7
could have had a significantly better effect of BCG vaccination
against the development of RW than children vaccinated on
days 0 or 1 if the sample size had been bigger. Thus timing of
the intervention might be important, although our trial cannot
prove this hypothesis.
The broad RW definition proposed in the analysis plan yielded
a very high prevalence of RW, and some of the comments written
during the telephone interviews and clinical examinations
revealed the low specificity of such a broad definition. The signs
and symptoms of RWare fluctuating and in milder cases difficult
to distinguish from typical symptoms of having a normal cold.
Thus we found it important to rely on stricter outcome criteria.Strengths and limitations
This is the largest RCTassessing the effect of neonatal BCG on
RW to date. With 98% of the included children interviewed at
13 months of age, we had a very high follow-up rate.
Our definition of RW required both a diagnosis of RW given by
a medical doctor and the use of antiasthma treatment, and thus we
emphasized a high specificity of the diagnosis.
A limitation was the impossibility of blinding the parents to
study allocation because no other injection can mimic the typical
reaction after a BCG vaccination. The study staff was blinded
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telephone interviews and at clinical examinations.
Because the symptoms of RW are fluctuating and some
children received treatment, children typically had no signs of
RWat the clinical examination, even if they were reported to have
had RW.
A limitation in the analysis of the broad definition of RW based
on 10 defining questions and proposed in the analysis plan (see
Table E1) was the relatively high number of missing answers.
However, it is reassuring that the results of the effect of BCG
by using our more specific definition were similar to those ob-
tained by using the broader definition.Implications
We found no association between BCG vaccination at birth and
the cumulative incidence of RW in the first year of life. Thus
neonatal BCG vaccination cannot be used as protection against
RW in a high-income country like Denmark. Moreover, the
possible side effects of a BCG vaccination should always be taken
into account before vaccinating an infant. In the Danish Calmette
Study we have previously reported the finding of an unexpectedly
high number of cases of suppurative lymphadenitis.25 Conversely,
BCGdid not result in significantlymore RW, and thereforewhen a
BCG vaccination is necessary for other reasons, the child can be
BCG vaccinated without concerns of RW.Conclusion
In this large RCT from a high-income country, neonatal BCG
had no effect on the cumulative incidence of RW in the first
13 months of life.
We thank the participating children and their families for their time, interest,
and loyalty, and we thank the Danish Calmette Study staff for their work and
commitment.
Clinical implications: Neonatal BCG vaccination had no effect
on the cumulative incidence of RW in the first year of life in
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TABLE E1. Broad definition, including any suspicion or sign, of RW in the first year of life in relation to neonatal BCG vaccination
and potential effect modifiers*
Parameter analyzed
BCG group,
no. with RW/total no. (%)
Control group,
no. with RW/total no. (%)
RR (95% CI) for
BCG effect on RW
Test of no
interaction
(P value)
Any suspicion or sign of RW, including
parent-suspected RW
330/1977 (16.7%) 300/1858 (16.1%) 1.03 (0.90-1.19)
RW in relation to potential effect modifiers
GA at birth
Premature (GA 3210 to 3616; n 5 118) 14/61 (23.0%) 10/57 (17.5%) 1.31 (0.63-2.71) .52
Mature (GA >_3710; n 5 3717) 316/1916 (16.5%) 290/1801 (16.1%) 1.02 (0.89-1.19)
Sex
Boys (n 5 2024) 202/1025 (19.7%) 193/999 (19.3%) 1.02 (0.86-1.22) .72
Girls (n 5 1811) 128/952 (13.4%) 107/859 (12.5%) 1.08 (0.85-1.37)
Atopic predisposition (missing: 66)
With atopic predisposition (n 5 2424) 220/1257 (17.5%) 196/1167 (16.8%) 1.04 (0.81-1.34) .99
Without atopic predisposition (n 5 1345) 107/683 (15.7%) 100/662 (15.1%) 1.04 (0.87-1.24)
Maternal BCG status (missing: 45)
Mother BCG vaccinated (n 5 657) 54/341 (15.8%) 38/316 (12.0%) 1.31 (0.89-1.93) .26
Mother not BCG vaccinated (n 5 3133) 271/1614 (16.8%) 259/1519 (17.1%) 0.99 (0.84-1.15)
Ethnicity (missing: 22)
Danish ethnicity (n 5 3085) 268/1630 (16.4%) 250/1455 (17.2%) 0.96 (0.82-1.12) .06
Non-Danish ethnicity (n 5 728) 61/336 (18.2%) 48/392 (12.2%) 1.49 (1.05-2.11)
Siblings (missing: 2)
No older siblings (n 5 2247) 171/1131 (15.1%) 131/1116 (11.7%) 1.29 (1.04-1.60) .002
At least 1 older sibling (n 5 1586) 159/846 (18.8%) 169/740 (22.8%) 0.82 (0.68-1.00)
Pets at home
Yes (n 5 1123) 102/604 (16.9%) 96/519 (18.5%) 0.91 (0.71-1.17) .25
No (n 5 2712) 228/1373 (16.6%) 204/1339 (15.2%) 1.09 (0.92-1.30)
Smoking status by 13 mo of age (missing: 28)
Ever smoked since birth of child (n 5 1045) 95/519 (18.3%) 95/526 (18.1%) 1.02 (0.79-1.32) .84
Never smoked since birth of child (n 5 2762) 232/1442 (16.1%) 202/1320 (15.3%) 1.05 (0.88-1.25)
Breast-feeding
Fully breast-fed until 3 mo of age (n 5 2187) 166/1136 (14.6%) 166/1051 (15.8%) 0.92 (0.76-1.13) .10
Not fully breast-fed until 3 mo (n 5 1648) 164/841 (19.5%) 134/807 (16.6%) 1.18 (0.96-1.45)
Started institutional child care before 13 mo of follow-up (missing: 1)
Yes (n 5 3302) 306/1717 (17.8%) 272/1585 (17.2%) 1.04 (0.90-1.21) .59
No (n 5 532) 24/260 (9.2%) 28/272 (10.3%) 0.90 (0.53-1.50)
GA, Gestational age.
*Log-binomial regression analysis of the 3835 children (90.0% of the randomized children) who answered all 10 defining questions regarding the broad definition of RW
(2 defining questions in each telephone interview and 3 at each clinical examination).
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TABLE E2. Sensitivity outcomes: RW in first year of life in relation to neonatal BCG vaccination—prevalence and RR for different
definitions of RW*
Parameter analyzed
BCG group,
no. with RW/
total no. (%)
Control group,
no. with RW/
total no. (%) RR (95% CI)
Broad definition of RW: any suspicion or sign of RW 330/1977 (16.7%) 300/1858 (16.1%) 1.03 (0.90-1.19)
Parent-suspected RW and/or medically diagnosed RW 316/2100 (15.0%) 290/2071 (14.0%) 1.03 (0.89-1.19)
Parent-suspected RW 286/2100 (13.6%) 263/2071 (12.7%) 1.08 (0.92-1.26)
Physician-diagnosed RW 234/2100 (11.1%) 214/2071 (10.3%) 1.08 (0.91-1.28)
Medically treated RW 233/2100 (11.1%) 213/2071 (10.3%) 1.08 (0.91-1.29)
RW found at the clinical examination§ 73/2001 (3.6%) 70/1879 (3.7%) 0.98 (0.71-1.35)
Any RW (telephone interview/clinical examination, including parent-suspected RW) 316/2100 (15.0%) 290/2071 (14.0%) 1.03 (0.89-1.19)
*Log-binomial regression.
The broad definition of RW is the primary outcome from the analysis plan. It includes parent-suspected RW, as well as rhonchi or prolonged expiration heard at auscultation.
The lower total number in the randomization group for this outcome reflects missing answers to 1 or more subquestions. The broad definition of RW is further elaborated in
Table E1.
Based on information given by the parents in the telephone interviews at 3 and 13 months of age.
§Based on clinical examinations at 3 and 13 months of age. Some children with telephone information concerning RW were not clinically examined.
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TABLE E3. Potential risk factors for cumulative incidence of physician-diagnosed and medically treated RW in the first year of life*
For all infants included: no. with RW/total no. (%)
Primary outcome: intention-to-treat analysis: physician-diagnosed and medically treated RW 406/4171 (9.7%)
RW in relation to potential effect modifiers
Subgroups,
no. with RW/total no. (%)
RR (95% CI) for RW in subgroups,
univariate analysis
RR (95% CI) for RW in subgroup,
multivariable analysis, n 5 4.006
GA at birth
Premature (GA 3210 to 3616; n 5 133) 15/133 (11.3%) 1.17 (0.72-1.89) 1.17 (0.85-1.24)
Mature (GA >_3710; n 5 4038) 391/4038 (9.7%) 1.0
Sex
Boys (n 5 2199) 258/2199 (11.7%) 1.56 (1.29-1.90) 1.62 (1.34-1.97)
Girls (n 5 1972) 148/1972 (7.5%) 1.0
Atopic predisposition (missing: 73)
With atopic predisposition (n 5 2630) 266/2630 (10.1%) 1.08 (0.89-1.32) 1.05 (0.87-1.28)
Without atopic predisposition (n 5 1468) 137/1468 (9.3%) 1.0
Maternal BCG status (missing: 51)
Mother BCG vaccinated (n 5 724) 51/724 (7.0%) 0.69 (0.52-0.91) 0.75 (0.56-1.00)
Mother not BCG vaccinated (n 5 3396) 348/3396 (10.2%) 1.0
Ethnicity (missing: 25)
Non-Danish ethnicity (n 5 824) 70/824 (8.5%) 0.84 (0.66-1.08) 0.92 (0.71-1.19)
Danish ethnicity (n 5 3322) 336/3322 (10.1%) 1.0
Siblings (missing: 2)
At least 1 older sibling (n 5 1724) 225/1724 (13.1%) 1.76 (1.46-2.12) 1.81 (1.50-2.18)
No older siblings (n 5 2445) 181/2445 (7.4%) 1.0
Pets at home
Yes (n 5 1225) 151/1225 (12.3%) 1.42 (1.18-1.72) 1.39 (1.15-1.68)
No (n 5 2946) 255/2946 (8.7%) 1.0
Smoking status by 13 mo of age (missing: 36)
Ever smoked since birth of child (n 5 1157) 131/1157 (11.3%) 1.24 (1.02-1.51) 1.24 (1.02-1.51)
Never smoked since birth of child (n 5 2978) 272/2978 (9.1%) 1.0
Breast-feeding (missing: 7)
Not fully breast-fed until 3 mo (n 5 1801) 193/1801 (10.7%) 1.18 (0.98-1.42) 1.24 (1.03-1.50)
Fully breast-fed until 3 mo of age (n 5 2363) 213/2363 (9.0%) 1.0
Started institutional child care before 13 mo of follow-up (missing: 1)
Yes (n 5 3584) 377/3584 (10.5%) 2.12 (1.47-3.07) 2.0 (1.38-2.90)
No (n 5 586) 29/586 (4.9%) 1.0
GA, Gestational age.
*Log-binomial regression analysis of the 4171 children who answered the questions regarding RW in the telephone interview at 13 months of age (97.9% of the randomized
children).
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